RBX7455

BIOLOGICAL2 trials

Sponsors

Mayo Clinic, Ochsner Health System

Conditions

Cirrhosis, LiverClostridium Difficile InfectionHepatic Encephalopathy

Phase 1

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

CompletedNCT02981316

Mayo ClinicClostridium Difficile Infection

Start: 2016-11-30End: 2020-07-22Updated: 2020-12-08

Phase 2

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

TerminatedNCT04155099

Ochsner Health SystemCirrhosis, Liver, Hepatic Encephalopathy

Start: 2021-03-01End: 2023-07-30Updated: 2023-10-03

Related Papers

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent <i>Clostridioides difficile</i> Infections

Clinical Infectious Diseases2020-09-1849 citations